CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,009 enrolled
Drug / intervention
Regadenoson +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00862641
NCT00862641Phase 4Completed

A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).

Astellas Pharma Inc·interventional·Posted Mar 17, 2009·Updated Sep 18, 2012

In Brief

A Phase 4 clinical trial evaluating Regadenoson and Placebo for Asthma and 2 related conditions. Completed, enrolled 1,009 participants across 48 sites.

Detailed Summary

This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.3 years ago

Interventions

Regadenosondrug

IV

Placebodrug

IV